Overweight and ObesityNCT03175081
Intraperitoneal Local Anesthetic in Bariatric Surgery Study (iLABS Study)
A study testing Ropivacaine and Normal saline in people with Overweight and Obesity and Bariatric Surgery Candidate, run by Dr. Tikfu Gee at 2 sites in Malaysia.
Trial summary
Obesity is a metabolic disorder that has gradually become a prevalent public health problem and is becoming one of the leading causes of death and disability worldwide. The most efficacious therapy for morbid obesity today is bariatric surgery. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Overweight and Obesity, Bariatric Surgery Candidate
- What is being tested?
- Ropivacaine and Normal saline
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 2 sitesMalaysia
- Study dates
- 27 Apr 2017to 27 Apr 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients age 18 years and above ii. Patients who can communicate in English or Malay iii. Patients undergoing elective laparoscopic sleeve gastrectomy iv. Able to give informed consent
Who cannot join
- Patients age below 18 years ii. Patients are allergic to ropivacaine or local anaesthetic iii. Inability to informed consent iv. American Society of Anesthesiologists Classification > 3 v. Patients with chronic medical diseases (eg. Ischaemic heart disease, cardiac arrhythmias, cardiac failure) and chronic opioid treatment vi. Patients with previous foregut surgery including esophageal, gastric, liver, and pancreas resections
Trial locations and contacts
2 sites in 1 country.
Malaysia2 sites
Hospital Serdang
Kajang, Selangor, 43400
Hospital Kuala Lumpur
Kuala Lumpur, Kuala Lumpur, 50586
About this study
Official title: Intraperitoneal Local Anesthetic in Bariatric Surgery: A Double Blind-randomized Controlled Pilot Trial
Obesity is a metabolic disorder that has gradually become a prevalent public health problem and is becoming one of the leading causes of death and disability worldwide. The most efficacious therapy for morbid obesity today is bariatric surgery. Bariatric surgery increases life expectancy by correcting the comorbidities associated with obesity, improves the quality of life, and is associated with reduced morbidity and mortality. There is an increase application of laparoscopic procedures as it is considered to cause less pain than traditional open surgery, smaller incision, reduced blood loss and shorter postoperative stay, which cuts down on hospital cost. However, postoperative pain still exists causing unpleasant experience for the patient and at times causes a delayed discharge. Pain after bariatric surgery is a result of many mechanisms such as tissue injury, abdominal distention, local trauma of the stomach, chemical irritation of the peritoneum, and the pneumoperitoneum and this pain potentially can prolong hospital stay and lead to increased morbidity, and bariatric surgeons are striving to minimize the morbidity of current procedures to improve patient outcomes and this gave rise to the use of intraperitoneal local anesthetics (LA). It was found that the use of intraperitoneal LA in laparoscopic cholecystectomy is safe, and it results in a statistically significant reduction in early postoperative abdominal pain. Many studies were done to evaluate the efficacy of intraperitoneal LA in laparoscopic cholecystectomy, gynecologic procedures and appendectomy but to date there are limited studies done to evaluate the role of intraperitoneal LA in bariatric surgery. The aim of this study is to evaluate the effectiveness of intraperitoneal instillation of local ropivacaine on postoperative abdominal pain after laparoscopic sleeve gastrectomy (LSG). We hypothesized that the administration of intraperitoneal instillation of local ropivacaine would help reduce postoperative pain.
Read the detailed description
Recruitment will be a double-blind, placebo-controlled randomized study in patients age 18 and above going for laparoscopic sleeve gastrectomy (LSG). The study will involve two groups with equal allocation of patients in the test group (local anaesthesia) and control group (normal saline) by randomization. All patient will need to be evaluated by our multidisciplinary team before randomization. Each patient going for an elective LSG will be informed regarding this research study, and the final decision will solely be made based on patients' willingness. All patients who agree to participate in this study will be randomized into one of the study groups. The patients will also be made aware that this is an experimental trial and both verbal and written informed consent will be taken before treatment. In addition, the patients will be informed regarding the use of the clinical and analytical data for publication purposes.
Patients will not be given access to the study data however they will be informed regarding their progress during every follow-up visit. All research data will be kept in our hard disk as well as our web-based storage (i-cloud and i-drive) for two years. Study data will be held even after the study period as there will still be a continuous follow-up with the patients for life. However, all patients' information obtained from this study will be kept and handled in a confidential manner, by applicable laws and regulations. When publishing or presenting the study results, the identity of patients will not be revealed without patient's expressed consent. Participants will also be covered under clinical trial insurance from the institution during the study period. In the case of emergency, all patients will be given the contact number of the investigator as the investigator are contactable throughout the day. This study will begin after receiving the approval of Medical Research \& Ethics Committee, Ministry of Health Malaysia.
Computer generated randomization will be done using Interactive Web Response Technology. There will be equal chances for patients to be assigned to either one of the study groups. The result of the randomization will be kept in envelopes and viewed by the research assistant who did not otherwise participate in this study, were unknown to the investigators and the patients, and the answer will be contained in a set of sealed envelopes. After admitting the patient into the operating room and just before the surgery was done, the numbered envelope will be opened by the operating theater nurse and the card inside determined which group the patient would be placed. The operating theater nurse will then prepare either 20mL of 150mg ropivacaine in 180mL normal saline (for test group) or 200mL normal saline (for control group) using a standard syringe and the syringe will be given to the surgeon who then injects the solution through a catheter along the greater curvature and left subdiaphragmatic region of the stomach. The general anesthetic used for all patients will be a combination of 1gm IV Paracetamol, 40mg IV Parecoxib and IV Fentamyl prepared according to patient's adjusted body weight.
Patients will need to be admitted to the hospital one day before the scheduled surgery date. Participating patients that are allergic to local anesthetic ropivacaine will be excluded from this study. However, if patients have allergy due to the medication after surgery, anti-allergic medication will be administered to the patients upon investigation. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). A score of 0 means no pain, whereas a score of 10 equals the worst pain ever experienced. Post-operative pain will be rated on a VAS at rest and cough. The time of arrival in the postoperative recovery room will be defined as zero hours postoperatively. The patients will be asked about the location of pain, whether at the shoulder, incision sites, and/or inside the abdomen by the medical doctors or nurses. The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively. The analgesic requirement during the 48 hours after the surgery will also be noted by the medical doctor or nurses in the ward. The duration of patients' participation in the study will only be for two days postoperative. However, patients still need to come for follow-up after surgery. The standard follow-up includes a visit to the outpatient clinic at 1, 2, 3, 4 weeks after surgery, then 3, 6, 9, 12, 18, 24 months and after that, a life-long annual visit. Adverse events (eg. post-operative bleeding and stapler leak) will be monitored closely at 1, 2, 3, and 4 weeks after surgery. In any occurrence of an adverse event, it will be documented and reported within 14 days.
Sample Size Estimation The sample size was estimated with the help of PS software (power and sample size calculation software) 3.0.43 with a power of 80% and a significant level of 0.05. The estimation was based on Visual Analog Score (VAS) with assuming 50% of difference in mean postoperative pain score. The total estimated sample size is 22 patients in each arm for our study. However, with the inclusion of 20% drop out rate, the total number of patients needed for this study is 27 patients in each arm.
Data Analysis Statistical calculations will be performed using the standard statistical software package, IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp. All data will be expressed as mean values and standard deviation, with the exception of rescue analgesic treatment and the occurrence of shoulder tip pain that will be in percentages (%). Median and interquartile range (IQR) will be calculated for all not normally distributed continuous variables. Non-parametric tests such as Mann-Whitney U test and/orKruskall-Wallis test will be used for non-normal distribution of variables. Associations between qualitative variables will be determined by Chi-square test, Fisher's exact test and SAS Exact Contingency Table. In all statistical analyses, p-value of < 0.05 (95% confidence interval) was considered to be statistically significant.
Study Ethics Ethical clearance will be obtained from the Medical Research Ethic Committee of the Faculty of Medicine, Universiti Putra Malaysia and Kuala Lumpur General Hospital. This study will be submitted for National Medical Research Register (NMRR). Respondent consent will be obtained from each participant of study.
Conflict of Interest There is no conflict of interest among the investigators.
- Being tested
- Ropivacaine, Normal saline
- Keywords
- Intraperitoneal local anesthetic, Ropivacaine, Postoperative pain, Bariatric surgery, Sleeve gastrectomy
- Medical subject headings
- Overweight, Obesity, Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RopivacaineDrug
Also called Test group
Patient undergo elective laparoscopic sleeve gastrectomy will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
Normal salineDrug
Also called Control group
Patient undergo elective laparoscopic sleeve gastrectomy will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
| Study group | Role | What they receive |
|---|---|---|
| Test group | Experimental | Patients will undergo elective laparoscopic sleeve gastrectomy with ropivacaine diluted in normal saline injected along the stomach region at the end of the surgical procedure. Receives: Drug: Ropivacaine |
| Control group | Experimental | Patients will undergo elective laparoscopic sleeve gastrectomy with only normal saline injected along the stomach region at the end of the surgical procedure. Receives: Drug: Normal saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
2 hours postoperative pain at rest
Measured by visual analogue pain scale
Measured: 2 hours after surgery
4 hours postoperative pain at rest
Measured by visual analogue pain scale
Measured: 4 hours after surgery
6 hours postoperative pain at rest
Measured by visual analogue pain scale
Measured: 6 hours after surgery
8 hours postoperative pain at rest
Measured by visual analogue pain scale
Measured: 8 hours after surgery
24 hours postoperative pain at rest
Measured by visual analogue pain scale
Measured: 24 hours after surgery
48 hours postoperative pain at rest
Measured by visual analogue pain scale
Measured: 48 hours after surgery
Secondary outcomes (6)
2 hours postoperative pain at cough
Measured by visual analogue pain scale
Measured: 2 hours after surgery
4 hours postoperative pain at cough
Measured by visual analogue pain scale
Measured: 4 hours after surgery
6 hours postoperative pain at cough
Measured by visual analogue pain scale
Measured: 6 hours after surgery
8 hours postoperative pain at cough
Measured by visual analogue pain scale
Measured: 8 hours after surgery
24 hours postoperative pain at cough
Measured by visual analogue pain scale
Measured: 24 hours after surgery
48 hours postoperative pain at cough
Measured by visual analogue pain scale
Measured: 48 hours after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2017
- Study start27 Apr 2017
- Primary completion27 Feb 2018
- Study completion27 Apr 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (21)Papers the sponsor has linked to this study.
- Other trials for Overweight and ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The study will involve two groups with equal allocation of patients in the test group (local anaesthesia) and control group (normal saline) by randomization. All patients who agree to participate in this study will be randomized into one of the study groups.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr. Tikfu Gee
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Dr. Tikfu Gee, Universiti Putra Malaysia
- Investigators
- Lim Shu Yu, MS, Principal investigator, Universiti Putra Malaysia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03175081
- Sponsor's protocol ID
- NMRR-17-284-33857
- Status last verified
- Jan 2021
- First submitted
- 24 May 2017
- Last updated
- 25 Jan 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Sjostrom L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes (Lond). 2008 Dec;32 Suppl 7:S93-7. doi: 10.1038/ijo.2008.244.
PubMed 19136998Lee YC, Lee CK, Liew PL, Lin YC, Lee WJ. Evaluation of quality of life and impact of personality in Chinese obese patients following laparoscopic sleeve gastrectomy. Hepatogastroenterology. 2011 Jul-Aug;58(109):1248-51. doi: 10.5754/hge10619.
PubMed 21937388Rosenthal RJ; International Sleeve Gastrectomy Expert Panel; Diaz AA, Arvidsson D, Baker RS, Basso N, Bellanger D, Boza C, El Mourad H, France M, Gagner M, Galvao-Neto M, Higa KD, Himpens J, Hutchinson CM, Jacobs M, Jorgensen JO, Jossart G, Lakdawala M, Nguyen NT, Nocca D, Prager G, Pomp A, Ramos AC, Rosenthal RJ, Shah S, Vix M, Wittgrove A, Zundel N. International Sleeve Gastrectomy Expert Panel Consensus Statement: best practice guidelines based on experience of >12,000 cases. Surg Obes Relat Dis. 2012 Jan-Feb;8(1):8-19. doi: 10.1016/j.soard.2011.10.019. Epub 2011 Nov 10.
PubMed 22248433Dixon JB, le Roux CW, Rubino F, Zimmet P. Bariatric surgery for type 2 diabetes. Lancet. 2012 Jun 16;379(9833):2300-11. doi: 10.1016/S0140-6736(12)60401-2. Epub 2012 Jun 9.
PubMed 22683132Wills VL, Hunt DR. Pain after laparoscopic cholecystectomy. Br J Surg. 2000 Mar;87(3):273-84. doi: 10.1046/j.1365-2168.2000.01374.x.
PubMed 10718794Parikh M, Issa R, McCrillis A, Saunders JK, Ude-Welcome A, Gagner M. Surgical strategies that may decrease leak after laparoscopic sleeve gastrectomy: a systematic review and meta-analysis of 9991 cases. Ann Surg. 2013 Feb;257(2):231-7. doi: 10.1097/SLA.0b013e31826cc714.
PubMed 23023201Pequignot A, Fuks D, Verhaeghe P, Dhahri A, Brehant O, Bartoli E, Delcenserie R, Yzet T, Regimbeau JM. Is there a place for pigtail drains in the management of gastric leaks after laparoscopic sleeve gastrectomy? Obes Surg. 2012 May;22(5):712-20. doi: 10.1007/s11695-012-0597-0.
PubMed 22328096Kim TH, Kang H, Hong JH, Park JS, Baek CW, Kim JY, Jung YH, Kim HK. Intraperitoneal and intravenous lidocaine for effective pain relief after laparoscopic appendectomy: a prospective, randomized, double-blind, placebo-controlled study. Surg Endosc. 2011 Oct;25(10):3183-90. doi: 10.1007/s00464-011-1684-3. Epub 2011 Apr 13.
PubMed 21487863Chazelet C, Verhaeghe P, Perterli R, Fennich S, Houdart R, Topart R, Tussiot J, Skawinski P, Seraille G, Catheline JM, Merabet M, Dehaye B, Pautot V, Juglard G, Sala JJ. [Longitudinal sleeve gastrectomy as a stand-alone bariatric procedure: Results of a multicenter retrospective study]. J Chir (Paris). 2009 Aug;146(4):368-72. doi: 10.1016/j.jchir.2009.08.021. Epub 2009 Sep 16. French.
PubMed 19762021Louizos AA, Hadzilia SJ, Leandros E, Kouroukli IK, Georgiou LG, Bramis JP. Postoperative pain relief after laparoscopic cholecystectomy: a placebo-controlled double-blind randomized trial of preincisional infiltration and intraperitoneal instillation of levobupivacaine 0.25%. Surg Endosc. 2005 Nov;19(11):1503-6. doi: 10.1007/s00464-005-3002-4. Epub 2005 Oct 3.
PubMed 16328673Elhakim M, Elkott M, Ali NM, Tahoun HM. Intraperitoneal lidocaine for postoperative pain after laparoscopy. Acta Anaesthesiol Scand. 2000 Mar;44(3):280-4. doi: 10.1034/j.1399-6576.2000.440310.x.
PubMed 10714840Barczynski M, Konturek A, Herman RM. Superiority of preemptive analgesia with intraperitoneal instillation of bupivacaine before rather than after the creation of pneumoperitoneum for laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled study. Surg Endosc. 2006 Jul;20(7):1088-93. doi: 10.1007/s00464-005-0458-1. Epub 2006 May 13.
PubMed 16703434Lepner U, Goroshina J, Samarutel J. Postoperative pain relief after laparoscopic cholecystectomy: a randomised prospective double-blind clinical trial. Scand J Surg. 2003;92(2):121-4.
PubMed 12841551Khan MR, Raza R, Zafar SN, Shamim F, Raza SA, Pal KM, Zafar H, Alvi R, Chawla T, Azmi R. Intraperitoneal lignocaine (lidocaine) versus bupivacaine after laparoscopic cholecystectomy: results of a randomized controlled trial. J Surg Res. 2012 Dec;178(2):662-9. doi: 10.1016/j.jss.2012.06.005. Epub 2012 Jun 22.
PubMed 22763212Malhotra N, Chanana C, Roy KK, Kumar S, Rewari V, Sharma JB. To compare the efficacy of two doses of intraperitoneal bupivacaine for pain relief after operative laparoscopy in gynecology. Arch Gynecol Obstet. 2007 Oct;276(4):323-6. doi: 10.1007/s00404-007-0337-1. Epub 2007 Jul 25.
PubMed 17653742
Study at a glance
From the registry record, last updated by the sponsor on 25 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intraperitoneal Local Anesthetic in Bariatric Surgery: A Double Blind-randomized Controlled Pilot Trial
- ClinicalTrials.gov ID
- NCT03175081
- Acronym / sponsor ID
- NMRR-17-284-33857
- Keywords
- Intraperitoneal local anesthetic, Ropivacaine, Postoperative pain, Bariatric surgery, Sleeve gastrectomy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- Dr. Tikfu GeeUniversity, hospital or other
- Study start
- 27 Apr 2017 (actual)
- Primary completion
- 27 Feb 2018 (actual)
- Study completion
- 27 Apr 2018 (actual)
- First posted
- 5 Jun 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obesity is a metabolic disorder that has gradually become a prevalent public health problem and is becoming one of the leading causes of death and disability worldwide. The most efficacious therapy for morbid obesity today is bariatric surgery. Bariatric surgery increases life expectancy by correcting the comorbidities associated with obesity, improves the quality of life, and is associated with reduced morbidity and mortality. There is an increase application of laparoscopic procedures as it is considered to cause less pain than traditional open surgery, smaller incision, reduced blood loss and shorter postoperative stay, which cuts down on hospital cost. However, postoperative pain still exists causing unpleasant experience for the patient and at times causes a delayed discharge. Pain after bariatric surgery is a result of many mechanisms such as tissue injury, abdominal distention, local trauma of the stomach, chemical irritation of the peritoneum, and the pneumoperitoneum and this pain potentially can prolong hospital stay and lead to increased morbidity, and bariatric surgeons are striving to minimize the morbidity of current procedures to improve patient outcomes and this gave rise to the use of intraperitoneal local anesthetics (LA). It was found that the use of intraperitoneal LA in laparoscopic cholecystectomy is safe, and it results in a statistically significant reduction in early postoperative abdominal pain. Many studies were done to evaluate the efficacy of intraperitoneal LA in laparoscopic cholecystectomy, gynecologic procedures and appendectomy but to date there are limited studies done to evaluate the role of intraperitoneal LA in bariatric surgery. The aim of this study is to evaluate the effectiveness of intraperitoneal instillation of local ropivacaine on postoperative abdominal pain after laparoscopic sleeve gastrectomy (LSG). We hypothesized that the administration of intraperitoneal instillation of local ropivacaine would help reduce postoperative pain.
Detailed description
Recruitment will be a double-blind, placebo-controlled randomized study in patients age 18 and above going for laparoscopic sleeve gastrectomy (LSG). The study will involve two groups with equal allocation of patients in the test group (local anaesthesia) and control group (normal saline) by randomization. All patient will need to be evaluated by our multidisciplinary team before randomization. Each patient going for an elective LSG will be informed regarding this research study, and the final decision will solely be made based on patients' willingness. All patients who agree to participate in this study will be randomized into one of the study groups. The patients will also be made aware that this is an experimental trial and both verbal and written informed consent will be taken before treatment. In addition, the patients will be informed regarding the use of the clinical and analytical data for publication purposes.
Patients will not be given access to the study data however they will be informed regarding their progress during every follow-up visit. All research data will be kept in our hard disk as well as our web-based storage (i-cloud and i-drive) for two years. Study data will be held even after the study period as there will still be a continuous follow-up with the patients for life. However, all patients' information obtained from this study will be kept and handled in a confidential manner, by applicable laws and regulations. When publishing or presenting the study results, the identity of patients will not be revealed without patient's expressed consent. Participants will also be covered under clinical trial insurance from the institution during the study period. In the case of emergency, all patients will be given the contact number of the investigator as the investigator are contactable throughout the day. This study will begin after receiving the approval of Medical Research \& Ethics Committee, Ministry of Health Malaysia.
Computer generated randomization will be done using Interactive Web Response Technology. There will be equal chances for patients to be assigned to either one of the study groups. The result of the randomization will be kept in envelopes and viewed by the research assistant who did not otherwise participate in this study, were unknown to the investigators and the patients, and the answer will be contained in a set of sealed envelopes. After admitting the patient into the operating room and just before the surgery was done, the numbered envelope will be opened by the operating theater nurse and the card inside determined which group the patient would be placed. The operating theater nurse will then prepare either 20mL of 150mg ropivacaine in 180mL normal saline (for test group) or 200mL normal saline (for control group) using a standard syringe and the syringe will be given to the surgeon who then injects the solution through a catheter along the greater curvature and left subdiaphragmatic region of the stomach. The general anesthetic used for all patients will be a combination of 1gm IV Paracetamol, 40mg IV Parecoxib and IV Fentamyl prepared according to patient's adjusted body weight.
Patients will need to be admitted to the hospital one day before the scheduled surgery date. Participating patients that are allergic to local anesthetic ropivacaine will be excluded from this study. However, if patients have allergy due to the medication after surgery, anti-allergic medication will be administered to the patients upon investigation. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). A score of 0 means no pain, whereas a score of 10 equals the worst pain ever experienced. Post-operative pain will be rated on a VAS at rest and cough. The time of arrival in the postoperative recovery room will be defined as zero hours postoperatively. The patients will be asked about the location of pain, whether at the shoulder, incision sites, and/or inside the abdomen by the medical doctors or nurses. The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively. The analgesic requirement during the 48 hours after the surgery will also be noted by the medical doctor or nurses in the ward. The duration of patients' participation in the study will only be for two days postoperative. However, patients still need to come for follow-up after surgery. The standard follow-up includes a visit to the outpatient clinic at 1, 2, 3, 4 weeks after surgery, then 3, 6, 9, 12, 18, 24 months and after that, a life-long annual visit. Adverse events (eg. post-operative bleeding and stapler leak) will be monitored closely at 1, 2, 3, and 4 weeks after surgery. In any occurrence of an adverse event, it will be documented and reported within 14 days.
Sample Size Estimation The sample size was estimated with the help of PS software (power and sample size calculation software) 3.0.43 with a power of 80% and a significant level of 0.05. The estimation was based on Visual Analog Score (VAS) with assuming 50% of difference in mean postoperative pain score. The total estimated sample size is 22 patients in each arm for our study. However, with the inclusion of 20% drop out rate, the total number of patients needed for this study is 27 patients in each arm.
Data Analysis Statistical calculations will be performed using the standard statistical software package, IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp. All data will be expressed as mean values and standard deviation, with the exception of rescue analgesic treatment and the occurrence of shoulder tip pain that will be in percentages (%). Median and interquartile range (IQR) will be calculated for all not normally distributed continuous variables. Non-parametric tests such as Mann-Whitney U test and/orKruskall-Wallis test will be used for non-normal distribution of variables. Associations between qualitative variables will be determined by Chi-square test, Fisher's exact test and SAS Exact Contingency Table. In all statistical analyses, p-value of < 0.05 (95% confidence interval) was considered to be statistically significant.
Study Ethics Ethical clearance will be obtained from the Medical Research Ethic Committee of the Faculty of Medicine, Universiti Putra Malaysia and Kuala Lumpur General Hospital. This study will be submitted for National Medical Research Register (NMRR). Respondent consent will be obtained from each participant of study.
Conflict of Interest There is no conflict of interest among the investigators.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- The study will involve two groups with equal allocation of patients in the test group (local anaesthesia) and control group (normal saline) by randomization. All patients who agree to participate in this study will be randomized into one of the study groups.
| Arm | Type | Receives |
|---|---|---|
| Test group | Experimental | Drug: RopivacainePatients will undergo elective laparoscopic sleeve gastrectomy with ropivacaine diluted in normal saline injected along the stomach region at the end of the surgical procedure. |
| Control group | Experimental | Drug: Normal salinePatients will undergo elective laparoscopic sleeve gastrectomy with only normal saline injected along the stomach region at the end of the surgical procedure. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients age 18 years and above ii. Patients who can communicate in English or Malay iii. Patients undergoing elective laparoscopic sleeve gastrectomy iv. Able to give informed consent
Key exclusion criteria (1 listed)
- Patients age below 18 years ii. Patients are allergic to ropivacaine or local anaesthetic iii. Inability to informed consent iv. American Society of Anesthesiologists Classification > 3 v. Patients with chronic medical diseases (eg. Ischaemic heart disease, cardiac arrhythmias, cardiac failure) and chronic opioid treatment vi. Patients with previous foregut surgery including esophageal, gastric, liver, and pancreas resections
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RopivacaineAlso: Test groupPatient undergo elective laparoscopic sleeve gastrectomy will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively. | Drug | Test group |
| Normal salineAlso: Control groupPatient undergo elective laparoscopic sleeve gastrectomy will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively. | Drug | Control group |
Primary outcome
2 hours postoperative pain at rest
Time frame: 2 hours after surgery
Measured by visual analogue pain scale
4 hours postoperative pain at rest
Time frame: 4 hours after surgery
Measured by visual analogue pain scale
6 hours postoperative pain at rest
Time frame: 6 hours after surgery
Measured by visual analogue pain scale
8 hours postoperative pain at rest
Time frame: 8 hours after surgery
Measured by visual analogue pain scale
24 hours postoperative pain at rest
Time frame: 24 hours after surgery
Measured by visual analogue pain scale
48 hours postoperative pain at rest
Time frame: 48 hours after surgery
Measured by visual analogue pain scale
6 secondary outcomes
2 hours postoperative pain at cough
Time frame: 2 hours after surgery
4 hours postoperative pain at cough
Time frame: 4 hours after surgery
6 hours postoperative pain at cough
Time frame: 6 hours after surgery
8 hours postoperative pain at cough
Time frame: 8 hours after surgery
24 hours postoperative pain at cough
Time frame: 24 hours after surgery
48 hours postoperative pain at cough
Time frame: 48 hours after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jan 2021.
- Background: PubMed 19136998Sjostrom L. Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study. Int J Obes (Lond). 2008 Dec;32 Suppl 7:S93-7. doi: 10.1038/ijo.2008.244.
- Background: PubMed 21937388Lee YC, Lee CK, Liew PL, Lin YC, Lee WJ. Evaluation of quality of life and impact of personality in Chinese obese patients following laparoscopic sleeve gastrectomy. Hepatogastroenterology. 2011 Jul-Aug;58(109):1248-51. doi: 10.5754/hge10619.
- Background: PubMed 22248433Rosenthal RJ; International Sleeve Gastrectomy Expert Panel; Diaz AA, Arvidsson D, Baker RS, Basso N, Bellanger D, Boza C, El Mourad H, France M, Gagner M, Galvao-Neto M, Higa KD, Himpens J, Hutchinson CM, Jacobs M, Jorgensen JO, Jossart G, Lakdawala M, Nguyen NT, Nocca D, Prager G, Pomp A, Ramos AC, Rosenthal RJ, Shah S, Vix M, Wittgrove A, Zundel N. International Sleeve Gastrectomy Expert Panel Consensus Statement: best practice guidelines based on experience of >12,000 cases. Surg Obes Relat Dis. 2012 Jan-Feb;8(1):8-19. doi: 10.1016/j.soard.2011.10.019. Epub 2011 Nov 10.
- Background: PubMed 22683132Dixon JB, le Roux CW, Rubino F, Zimmet P. Bariatric surgery for type 2 diabetes. Lancet. 2012 Jun 16;379(9833):2300-11. doi: 10.1016/S0140-6736(12)60401-2. Epub 2012 Jun 9.
- Background: PubMed 10718794Wills VL, Hunt DR. Pain after laparoscopic cholecystectomy. Br J Surg. 2000 Mar;87(3):273-84. doi: 10.1046/j.1365-2168.2000.01374.x.
- Background: PubMed 23023201Parikh M, Issa R, McCrillis A, Saunders JK, Ude-Welcome A, Gagner M. Surgical strategies that may decrease leak after laparoscopic sleeve gastrectomy: a systematic review and meta-analysis of 9991 cases. Ann Surg. 2013 Feb;257(2):231-7. doi: 10.1097/SLA.0b013e31826cc714.
- Background: PubMed 22328096Pequignot A, Fuks D, Verhaeghe P, Dhahri A, Brehant O, Bartoli E, Delcenserie R, Yzet T, Regimbeau JM. Is there a place for pigtail drains in the management of gastric leaks after laparoscopic sleeve gastrectomy? Obes Surg. 2012 May;22(5):712-20. doi: 10.1007/s11695-012-0597-0.
- Background: PubMed 21487863Kim TH, Kang H, Hong JH, Park JS, Baek CW, Kim JY, Jung YH, Kim HK. Intraperitoneal and intravenous lidocaine for effective pain relief after laparoscopic appendectomy: a prospective, randomized, double-blind, placebo-controlled study. Surg Endosc. 2011 Oct;25(10):3183-90. doi: 10.1007/s00464-011-1684-3. Epub 2011 Apr 13.
- Background: PubMed 19762021Chazelet C, Verhaeghe P, Perterli R, Fennich S, Houdart R, Topart R, Tussiot J, Skawinski P, Seraille G, Catheline JM, Merabet M, Dehaye B, Pautot V, Juglard G, Sala JJ. [Longitudinal sleeve gastrectomy as a stand-alone bariatric procedure: Results of a multicenter retrospective study]. J Chir (Paris). 2009 Aug;146(4):368-72. doi: 10.1016/j.jchir.2009.08.021. Epub 2009 Sep 16. French.
- Background: PubMed 16328673Louizos AA, Hadzilia SJ, Leandros E, Kouroukli IK, Georgiou LG, Bramis JP. Postoperative pain relief after laparoscopic cholecystectomy: a placebo-controlled double-blind randomized trial of preincisional infiltration and intraperitoneal instillation of levobupivacaine 0.25%. Surg Endosc. 2005 Nov;19(11):1503-6. doi: 10.1007/s00464-005-3002-4. Epub 2005 Oct 3.
- Background: PubMed 10714840Elhakim M, Elkott M, Ali NM, Tahoun HM. Intraperitoneal lidocaine for postoperative pain after laparoscopy. Acta Anaesthesiol Scand. 2000 Mar;44(3):280-4. doi: 10.1034/j.1399-6576.2000.440310.x.
- Results publication: PubMed 16703434Barczynski M, Konturek A, Herman RM. Superiority of preemptive analgesia with intraperitoneal instillation of bupivacaine before rather than after the creation of pneumoperitoneum for laparoscopic cholecystectomy: a randomized, double-blind, placebo-controlled study. Surg Endosc. 2006 Jul;20(7):1088-93. doi: 10.1007/s00464-005-0458-1. Epub 2006 May 13.
- Individual participant dataSharing planned: No
Related trials for Overweight and Obesity
RecruitingPhase 4
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
Class I/II Obesity
Not yet recruitingObservational study
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
Healthy Volunteer, Obestity
RecruitingPhase 1/2
A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
Overweight and Obesity
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Not yet recruitingObservational study
A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesity
Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lim Shu Yu, MS principal investigator
Universiti Putra Malaysia
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Ropivacaine and Normal saline in people with Overweight and Obesity and Bariatric Surgery Candidate, run by Dr. Tikfu Gee at 2 sites in Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
2 hours postoperative pain at rest (time frame: 2 hours after surgery). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03175081, which also lists 21 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2021.